about
Circulating miRNA-122 levels are associated with hepatic necroinflammation and portal hypertension in HIV/HCV coinfection.Boceprevir or Telaprevir Based Triple Therapy against Chronic Hepatitis C in HIV Coinfection: Real-Life Safety and Efficacy.PRO-C3-levels in patients with HIV/HCV-Co-infection reflect fibrosis stage and degree of portal hypertensionProton pump inhibitor intake neither predisposes to spontaneous bacterial peritonitis or other infections nor increases mortality in patients with cirrhosis and ascites.IFNL4 ss469415590 variant shows similar performance to rs12979860 as predictor of response to treatment against Hepatitis C Virus genotype 1 or 4 in CaucasiansAssociation of CMV-Specific T Cell-Mediated Immunity with CMV DNAemia and Development of CMV Disease in HIV-1-Infected Individuals.The Impact of PNPLA3 rs738409 SNP on Liver Fibrosis Progression, Portal Hypertension and Hepatic Steatosis in HIV/HCV CoinfectionConversion from Tacrolimus to Cyclosporine A Improves Glucose Tolerance in HCV-Positive Renal Transplant Recipients.Impact of Early Initiation of Antiretroviral Therapy in Patients with Acute HIV Infection in Vienna, Austria.Interferon-free regimens improve health-related quality of life and fatigue in HIV/HCV-coinfected patients with advanced liver disease: A retrospective study.HCV targeting of patients with cirrhosis.Advances in the management of HIV/HCV coinfection.Beta blockers and cirrhosis, 2016.The trigger matters - outcome of hepatorenal syndrome vs. specifically triggered acute kidney injury in cirrhotic patients with ascites.HCV reinfection incidence and spontaneous clearance rates in HIV-positive men who have sex with men in Western Europe.Sustained virologic response to interferon-free therapies ameliorates HCV-induced portal hypertension.Plasma renin concentration represents an independent risk factor for mortality and is associated with liver dysfunction in patients with cirrhosis.Interferon-free treatment with sofosbuvir/daclatasvir achieves sustained virologic response in 100% of HIV/hepatitis C virus-coinfected patients with advanced liver disease.Treatment intensification with boceprevir in HIV-positive patients with acute HCV-genotype 1 infection at high risk for treatment failure.Impact of acute kidney injury on prognosis of patients with liver cirrhosis and ascites: A retrospective cohort study.Risk factors for development of spontaneous bacterial peritonitis and subsequent mortality in cirrhotic patients with ascites.Interferon-free regimens for chronic hepatitis C overcome the effects of portal hypertension on virological responses.Response-guided boceprevir-based triple therapy in HIV/HCV-coinfected patients: the HIVCOBOC-RGT study.New reliability criteria for transient elastography increase the number of accurate measurements for screening of cirrhosis and portal hypertension.The association of smoking with IGRA and TST results in HIV-1-infected subjects.Revisiting liver disease progression in HIV/HCV-coinfected patients: the influence of vitamin D, insulin resistance, immune status, IL28B and PNPLA3.Therapeutic potential of and treatment with boceprevir/telaprevir-based triple-therapy in HIV/chronic hepatitis C co-infected patients in a real-world setting.Strategies for assignment of HIV-HCV genotype-1-coinfected patients to either dual-therapy or direct-acting antiviral agent-based triple-therapy.Revisiting predictors of virologic response to PEGIFN + RBV therapy in HIV-/HCV-coinfected patients: the role of metabolic factors and elevated GGT levels.Reversion and conversion of interferon-γ release assay results in HIV-1-infected individuals.The impact of interleukin 28B rs12979860 single nucleotide polymorphism and liver fibrosis stage on response-guided therapy in HIV/HCV-coinfected patients.Viral determinants predicting hepatitis B surface antigen (HBsAg) seroclearance in HIV-/HBV-coinfected patients.Health-related quality of life and severity of fatigue in HIV/HCV co-infected patients before, during, and after antiviral therapy with pegylated interferon plus ribavirin.Low vitamin D levels are associated with impaired virologic response to PEGIFN + RBV therapy in HIV-hepatitis C virus coinfected patients.The influence of portal pressure on the discordance between absolute CD4+ cell count and CD4+ cell percentage in HIV/hepatitis C virus-coinfected patients.Erectile dysfunction in cirrhosis is impacted by liver dysfunction, portal hypertension, diabetes and arterial hypertension.Letter: sustained virological response and liver healing - authors' reply.Betablockers do not increase efficacy of band ligation in primary prophylaxis but they improve survival in secondary prophylaxis of variceal bleeding.Von Willebrand factor indicates bacterial translocation, inflammation, and procoagulant imbalance and predicts complications independently of portal hypertension severity.Prevention of progression from small to large varices: are we there yet? An updated meta-analysis.
P50
Q30418874-370F6954-BEBA-4D4A-AEB5-1C2E70E7FF84Q33422417-0AEF27BA-9DCA-45E0-8513-3751C9636C3BQ34268818-7B5A66A0-7057-432B-89AE-B7CCF1453A28Q34450128-4F0F424D-60C9-40D7-9EFD-EF79B41EF62BQ35153222-5EC4DF2E-B1C7-4EDB-B8C8-7DB10A0FFEFBQ35760200-0B54911B-184A-4C85-9768-CF1FE0461F78Q35849638-3C487D20-B0CD-490D-B92E-98D042F0D6C1Q35886733-34A5DF59-2C12-48A8-903A-1361F3499DB9Q35985891-7302EC1F-E911-4D15-88E4-E7D1BAB12B5FQ37327979-24BFAB86-3EB3-45F1-B130-6ABE6FD84CD1Q38534820-BFE58FFE-E572-42BE-B1B0-CA452091976CQ38693820-28176F63-2F23-493C-B404-323F67A66D0DQ38975429-BDA53E87-F6C6-41F1-8524-1262A75F5FA3Q39773776-59F1CC9C-61D4-4B3F-A50D-B1DC25937267Q40533477-9B2F4BAB-DBE9-4A12-AF64-75CF0DAFA42CQ40727706-2063B175-AC86-41DF-8195-73C0BFA10E8DQ40761529-BA33BBED-E478-475C-9745-A3F01E43153DQ40835311-3BB537F2-3832-49BE-A5E2-0BFFA8E7206BQ40873991-C68B054A-E430-483A-8807-55033981775CQ40946333-6875FA63-D085-4042-935B-F42E0EC17AE4Q41508212-3EFF6BB1-D6D2-4270-8247-3F4DFDECBEF6Q41582122-128793D0-E1D8-4177-BF9A-C4F28A2A9B50Q41741824-7CB17CEE-7A61-4B3B-B5E0-603C6C46E326Q42210807-C34A6883-93A2-48D9-8077-3AD64197B0FFQ42211834-BF240AC4-9741-4DAF-A2FA-32B64F89372DQ42213984-DEEEADCA-4C98-434A-A82C-83CE09114587Q42220481-36F615A9-FAE0-4F47-842A-60D5ACAB50AAQ42248749-1967DF6F-1D52-4219-BE6D-8F5B58CA293AQ42249709-0708F900-D1EB-4486-9FA7-708860EB2C8DQ42252628-8CE1A0CD-BB72-4281-929A-0D2EAF54D352Q42255967-C1900CC3-7243-4968-9265-A0E1FF6107D6Q42263556-3570F505-129F-4078-B4D7-E14F3D30A6E1Q42281169-A4FEC6C8-953D-4EC4-8928-3BF8AE59A8B3Q42987249-1B62CEF3-123C-4FA0-8441-4CE2A3AB23D4Q45353464-947BFB4A-5291-4C6C-B5D0-F7225E2FAD6CQ47549053-85F7BF77-4CE3-4B6F-91A0-C2382FB8ADE4Q48094950-D37EB75B-5C45-40B2-A31B-053DCDD79860Q48127274-33E0559A-6B3E-4A9C-86AE-7BE18D4C6196Q48152076-494EBED6-9659-4700-A62B-3DB777FA2435Q48326607-5AC3B8BF-5725-4820-AEB0-2CC493628518
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Mattias Mandorfer
@ast
Mattias Mandorfer
@en
Mattias Mandorfer
@es
Mattias Mandorfer
@sl
type
label
Mattias Mandorfer
@ast
Mattias Mandorfer
@en
Mattias Mandorfer
@es
Mattias Mandorfer
@sl
prefLabel
Mattias Mandorfer
@ast
Mattias Mandorfer
@en
Mattias Mandorfer
@es
Mattias Mandorfer
@sl
P106
P21
P31
P496
0000-0003-2330-0017